BioPharma Drug Discovery
China’s Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody target...
November 07, 2024 | News
Medidata Introduces Oncology and Vaccine Solutions to Streamline Phase II and III Trials with FDA-Aligned Patient-Centric Design
The new products combine Medidata's diverse technologies and experience from thousands of previous trials to streamline the management of Phase II an...
November 05, 2024 | News
Breast Cancer Drug Shows Promise for Treating Hereditary Hemorrhagic Telangiectasia, a Rare Vascular Disorder
A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia (HHT) – a rare genetic ble...
November 05, 2024 | News
Senhwa Biosciences Appoints Dr. Yiu-Lian Fong to Board of Directors for Strategic Growth in Oncology and Precision Medicine
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious disea...
November 04, 2024 | News
Taiwan’s CStone Secures UK Approval for Sugemalimab as First-Line Treatment for Metastatic NSCLC
This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the Eur...
November 01, 2024 | News
Taiwan’s Formosa Pharmaceuticals Partners with Portugal’s DÁVI Farmacêutica to Introduce APP13007 for Post-Surgical Ocular Pain Relief in Europe
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with DÁVI Far...
November 01, 2024 | News
Thermo Fisher’s $22M OSD Investment: Shervin Hebbi on Accelerating Drug Development with Cutting-Edge Technology
In an exclusive Q&A with BioPharma APAC, Shervin Hebbi, Vice President of Oral Solid Dose (OSD) – North America at Thermo Fisher ...
November 01, 2024 | Interview
Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy
Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...
October 31, 2024 | News
GC Biopharma and Novelty Nobility Join Forces to Develop New Antibody Therapy for Geographic Atrophy in Age-Related Macular Degeneration
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeut...
October 29, 2024 | News
South Korea’s Qurient Launches Phase 1 Clinical Trial for Adrixetinib in AML Following FDA IND Clearance
Qurient has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (...
October 25, 2024 | News
EpiVax and CUBRC Secure $2M FDA Contract to Develop T Cell Assay Standards for Generic Drug Immunogenicity
EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the...
October 25, 2024 | News
Australia's Telix Pharmaceuticals Secures FDA Priority Review for Pixclara® (TLX101-CDx) Glioma Imaging Agent
Telix Pharmaceuticals announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...
October 24, 2024 | News
RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research
RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...
October 23, 2024 | News
Angelini Pharma Secures Global and Asia Licensing Option for Brain Health Compound CV-01 in Partnership with Cureverse
The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel...
October 23, 2024 | News
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
